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Abstract: Psoriasis is a chronic inflammatory systemic disease for which there exist topical, 
ultraviolet, systemic, and biologic treatments. Biologic agents selectively interfere with the 
immune mechanisms responsible for psoriasis. Etanercept, infliximab, and adalimumab target 
tumor necrosis factor-alpha and have demonstrated efficacy in the treatment of psoriasis and 
psoriatic arthritis. Alefacept and efalizumab target T lymphocytes, are effective in the treatment 
of psoriasis, but are not approved for psoriatic arthritis. Finally, ustekinumab and ABT-874 
target interleukin-12 and interleukin-23, and they have demonstrated efficacy in the treatment 
of psoriasis. The objective of this review is to present efficacy and safety data from randomized 
controlled trials of the biologic agents in the treatment of psoriasis.
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Introduction
Psoriasis is a chronic inflammatory systemic disease which affects approximately 1% 
to 3% of the world’s population,1 and it is the most prevalent immune-mediated skin 
disease in adults.2 Psoriasis can have significant physical, psychological, and economic 
impacts on patients, leading to reduced quality of life,3–9 especially for patients with 
severe disease.10 Approximately 25% of patients have moderate to severe psoriasis.11 
Additionally, individuals with psoriasis have increased incidence of other chronic 
disorders including metabolic syndrome, coronary artery disease, diabetes mellitus, 
hypertension, fatigue, and depression.12–15
Depending on the study, between 5% and 42% of psoriasis patients develop pso-
riatic arthritis (PsA).16 PsA, once considered a benign arthropathy, is in fact a severe 
disease. A growing body of literature suggests that PsA is often progressive and is 
associated with accelerated mortality, substantial morbidity, and impaired quality of 
life.17,18
Conventional systemic treatments for moderate to severe psoriasis, including 
phototherapy with ultraviolet B (UVB), photochemotherapy with psoralens and 
ultraviolet A (PUVA), methotrexate, cyclosporine, and acitretin are limited by 
well-known and characteristic side effects, incomplete effectiveness in some patients, 
and demanding treatment schedules which result in decreased patient compliance.19 
Likewise, treatment of moderate to severe PsA with conventional disease modifying 
anti-rheumatic drugs (DMARDs) has not uniformly been shown to have efficacy, 
especially in treating cutaneous symptoms.20–23 A meta-analysis of published randomized 
controlled trials (RCTs) on DMARDs found that only parenteral high-dose methotrexate Clinical, Cosmetic and Investigational Dermatology 2009:2 112
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and sulfasalazine had efficacy in PsA,24 while another trial 
showed moderate efficacy of leflunomide in PsA.25 
The biologic agents have greatly increased the treatment 
choices for patients with moderate to severe psoriasis as 
well as those with moderate to severe PsA. The biologics 
used in treating psoriasis and PsA may be categorized 
as those inhibiting tumor necrosis factor-alpha (TNF-α) 
(ie, etanercept, infliximab, adalimumab), those inhibiting 
T cells (ie, efalizumab, alefacept), and those that block 
interleukin-12 and interleukin-23 (IL-12/23) (ie, ustekinumab, 
ABT-874).
Biologic agents should be used with caution, as robust, 
long-term data in psoriasis are not yet available. Physicians 
must continue to monitor for long-term adverse events such 
as chronic immunosuppression, which may lead to increased 
risks of infection and malignancy.2 It is also important to 
consider the high cost of biologic agents and the patient 
selection criteria used thus far in clinical trials and other 
studies.26 Before initiating therapy with a biologic agent, 
patients must be screened (Table 1) to ensure that they are 
appropriate candidates and to minimize adverse events.
Role of   TNF-α in psoriasis
TNF-α is a pro-inflammatory cytokine that is a member of a 
growing family of cytokines known as the TNF superfamily.27 
Binding of TNF-α to its receptors induces downstream sig-
naling that ultimately augments the expression of pro-inflam-
matory genes.27,28 TNF-α has numerous effects important in 
the pathogenesis of psoriasis and PsA. TNF-α production 
and activity are elevated in lesional psoriatic skin compared 
with non-lesional psoriatic skin and non-psoriatic skin.29–32 
TNF-α production and activity have also been shown to 
be higher in non-lesional psoriatic skin than non-psoriatic 
skin.30 Furthermore, serum TNF-α levels are higher in indi-
viduals with psoriasis than those without it,33,34 and synovial 
fluid TNF-α levels are higher in individuals with PsA.35–37 
Lesional and serum TNF-α levels correlate with psoriasis 
disease severity as measured by the psoriasis area and sever-
ity index (PASI)31 score. With effective therapy and clinical 
improvement, psoriasis patients exhibit decreased levels of 
lesional skin and serum TNF-α.33–39
Etanercept
Etanercept is a dimeric fusion protein consisting of the 
extracellular ligand-binding domain of the human TNF-α 
receptor fused to the constant fragment (Fc domain) of human 
immunoglobulin G1 (IgG1).27 It is currently approved by 
the Food and Drug Administration (FDA) for the treatment 
of moderate to severe psoriasis, moderate to severe PsA, 
adult rheumatoid arthritis, juvenile rheumatoid arthritis in 
patients as young as 4 years old, and ankylosing spondylitis. 
Etanercept is administered via subcutaneous injection (SC), 
and the FDA-approved regimen for psoriasis is 50 mg twice 
weekly (BIW) for 12 weeks followed by 50 mg weekly (QW) 
thereafter. Although numerous clinical trials have been con-
ducted with etanercept 25 mg BIW,40–42 recent studies have 
shown etanercept 50 mg QW to have comparable efficacy, 
safety, and pharmacokinetic profiles, with improved con-
venience.43,44 In a study in which subjects were treated with 
etanercept 50 mg BIW for 12 weeks followed by 12 weeks of 
etanercept 25 mg BIW, 77% of subjects maintained response 
despite dose reduction.45 For PsA, the dosing regimen is 
25 mg BIW or 50 mg QW, and etanercept is often used in 
combination with methotrexate.
Improvement in PsA may be noticeable as soon as 2 
weeks after starting treatment, while skin improvement is 
usually slower.46 In one trial, improvements in psoriasis 
were observed for up to 96 weeks with continuous etanercept 
therapy, with a peak in response after 48 weeks of treatment.47 
Nevertheless, etanercept loses efficacy over time in some 
patients, possibly due to the development of antibodies. 
In one open-label trial, clinical response was maintained in 
a higher proportion of psoriasis patients treated with continu-
ous rather than as-needed etanercept therapy;48 however, the 
trial only examined one round of re-treatment, and patients 
in the continuous group received more total medication. 
Patients do not typically experience rebound psoriasis after 
etanercept is discontinued.45,48,49
In contrast to infliximab and adalimumab, etaner-
cept is able to bind to both TNF-α and lymphotoxin-α 
Table 1 recommended actions before initiating biologic therapy 
for psoriasis and psoriatic arthritis
Age appropriate history
Physical examination
Current medication list
Baseline laboratory tests
  Liver function tests
  Complete blood cell count, including platelet count
  Hepatitis panel
  Tuberculosis skin test (PPD)
  Urine pregnancy test
ensure up-to-date status in standard vaccinations, including 
pneumococcal, hepatitis A and B, influenza, tetanus-diphtheria
Abbreviation: PPD, purified protein derivative.Clinical, Cosmetic and Investigational Dermatology 2009:2 113
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(TNF-β), although the clinical significance of its binding 
to lymphotoxin-α is unknown.50 Since etanercept has two 
binding sites for TNF-α, it binds TNF-α with greater affin-
ity than do natural monomeric receptors.51 Consequently, 
etanercept competitively inhibits membrane-associated and 
soluble TNF-α from binding its natural receptors and induc-
ing downstream signal transduction, resulting in a decrease 
in inflammatory activity.
Although excessive TNF-α contributes to the pathogenesis 
of psoriasis and PsA, a physiological level of TNF-α is 
important in protecting the body against opportunistic 
infection and malignancy. Hence, TNF-α antagonists 
should be administered in doses within the therapeutic 
window, reducing systemic and local TNF-α levels to 
within physiologically normal ranges but not so low as 
to lead to adverse events.52,53 Unlike infliximab and similar to 
adalimumab, the combination of slow absorption rate follow-
ing SC administration, slow elimination rate, and appropriate 
dosing frequency give etanercept a smooth and uniform 
concentration-time profile, minimizing the occurrence 
of overexposure and resultant adverse events, as well as 
underexposure and consequent symptom recurrence.52,53
Obesity, defined as body mass index (BMI) greater than 
or equal to 30 kg/m2, is on the rise.54 Recent studies have 
demonstrated higher prevalence of obesity and overweight 
in individuals with psoriasis than those without psoriasis.55–58 
Obese patients also tend to have more severe psoriasis than 
those with psoriasis who are not obese. Additionally, some 
conditions associated with obesity, such as nonalcoholic 
fatty liver disease, are relative contraindications to systemic 
treatments for psoriasis.59
Etanercept is administered via a fixed-dose regimen that 
is not dependent on the patient’s weight. Gordon et al49 per-
formed subgroup analyses of data pooled from three large 
clinical trials. Among all subjects receiving etanercept, a 75% 
or greater reduction in the psoriasis area and severity index 
score (PASI 75 response) was achieved by 47% of subjects 
weighing less than and 33% of those weighing greater than 
the median weight (89.36 kg). Strober et al60 conducted a 
subgroup analysis of a phase III trial where 618 patients were 
randomized to receive etanercept 50 mg SC BIW or pla-
cebo.61 “Superior response” was defined as PASI 90 response 
at 3 or more visits, and “sub-optimal response” was defined 
as failure to attain at least PASI 50 response at 3 or more 
visits. Superior response was achieved by 41% of normal-
weight subjects and 15% of extremely obese (BMI  40) 
subjects. Sub-optimal response was reported in only 9% of 
normal-weight patients, compared to 27% of extremely obese 
patients. These results suggest that normal-weight patients 
have a greater response to etanercept than heavier patients 
and support the idea of using etanercept less frequently in the 
most overweight patients. Interestingly, recent reports sug-
gest that treatment with the TNF-α inhibitors, but not with 
efalizumab or methotrexate, may lead to weight gain.62
There have been a number of clinical trials assessing 
the efficacy and safety of etanercept in treating psoriasis 
and PsA (Table 2) as well as demonstrating improvement 
in dermatology-related quality of life.61,63,64 Furthermore, 
etanercept is the only biologic agent that has data in pediatric 
and adolescent psoriasis patients, and it has demonstrated 
efficacy and safety in this patient population.65
The most common adverse events (AEs) with etan-
ercept use are injection site reaction and infection. Other 
common AEs include fever, headache, mild allergic reac-
tion, and pruritus. There exist rare reports of anaphylaxis, 
angioedema, exacerbation of or new-onset congestive heart 
failure (CHF), cytopenia, increased liver function tests 
(LFTs), leukocytoclastic vasculitis, lupus erythematosus 
syndrome, malignancy (eg, Hodgkin’s lymphoma, cutane-
ous T-cell lymphoma (CTCL), nonmelanoma skin cancer 
[NMSC]), multiple sclerosis (MS) or other demyelinating 
disease, sepsis, severe infection (eg tuberculosis [TB]), and 
urticaria.41,42,49,50, 66–69 The incidence of AEs, serious adverse 
events (SAEs), and infection occurring in clinical trials of 
etanercept is summarized in Table 2.
Contraindications for etanercept use include chronic, 
active, serious, and recurrent infection, active TB, latent TB 
in the absence of chemoprophylaxis, hepatitis B, MS and 
other demyelinating disease, a first-degree relative with MS, 
New York Heart Association (NYHA) class III or IV CHF, 
pregnancy or lactation, and hypersensitivity to etanercept or 
its ingredients. During treatment with etanercept, patients 
should avoid live and live-attenuated vaccines. Table 3 
lists monitoring recommendations for all TNF-α inhibitors. 
Note that most safety information about TNF-α inhibitors 
is derived from studies of their use in rheumatoid arthritis 
and inflammatory bowel disease.66
Infliximab
Infliximab is a chimeric TNF-α monoclonal antibody 
consisting of the human constant and mouse variable 
regions of the IgG antibody.70 It is currently FDA-approved 
for treating severe psoriasis, moderate to severe PsA, adult 
rheumatoid arthritis, ankylosing spondylitis, adult and 
pediatric Crohn’s disease, and ulcerative colitis. Infliximab 
is administered via intravenous infusions (IV) which span Clinical, Cosmetic and Investigational Dermatology 2009:2 114
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2 to 3 hours per session. For psoriasis and PsA, infliximab 
is given at a dose of 5 mg/kg at weeks 0, 2, and 6, followed 
by maintenance infusions every 6 to 8 weeks.
Clinical response to infliximab can be quite rapid, with 
significantly higher PASI improvements than placebo as 
early as 2 weeks after starting treatment.11,71–73 In one meta-
analysis, Brimhall et al noted that the relative risk (RR) of 
PASI 75 achievement was higher with infliximab than with 
any of the other biologic agents.69 Another meta-analysis 
found infliximab to have superior efficacy for treating 
moderate to severe psoriasis than adalimumab, etanercept, 
efalizumab, alefacept, methotrexate, cyclosporine, acitretin, 
and fumaric acid ester.74
Loss of efficacy may occur over time with infliximab 
treatment, especially in patients who do not achieve stable 
infliximab serum concentrations.75 This loss of efficacy 
may be due to the development of anti-chimeric antibodies. 
Clinical responses are better and patients are less likely to 
develop antibodies against infliximab if they are treated con-
tinuously rather than as-needed.72 Low-dose methotrexate or 
other immunosuppressive agents are sometimes prescribed 
concurrently with infliximab to help maintain infliximab’s 
efficacy over time; this may be due to a reduction in the 
formation of antibodies.76
Infliximab binds to and neutralizes soluble and 
membrane-bound TNF-α with high specificity, affinity, 
and avidity, thereby decreasing inflammation.77 It is even 
able to inactivate TNF-α bound to TNF receptors.11 The 
infliximab/TNF-α complex is much more stable than the 
etanercept/TNF-α complex.78
The IV administration of infliximab, along with its 
long elimination half-life, significant loading doses (630 to 
2100 mg administered within 6 weeks for a 70-kg patient), 
and relatively high maintenance doses (210 to 700 mg for a 
70-kg patient) create concentration-time profiles with very 
high peaks and low troughs.52,53,71 Although this pharmaco-
kinetic profile is not the most desirable one, the high efficacy 
rates of infliximab may balance these effects.
Unlike etanercept and adalimumab, infliximab dosing 
is weight-based. In a subgroup analysis of 1462 subjects in 
three RCTs of infliximab for moderate to severe psoriasis, 
Reich et al demonstrated infliximab’s comparable efficacy 
in subjects of varying weights.79 Similar proportions of 
overweight (78%), obese (74%), and normal-weight (78%) 
subjects achieved PASI 75 response.
A number of clinical trials have demonstrated the efficacy 
and safety of infliximab in treating psoriasis and PsA (Table 2). 
According to one meta-analysis, patients treated with inflix-
imab had a higher rate of adverse events compared to those 
treated with placebo (RR = 1.18, P  0.001).69 Infusion 
reactions are among the most common AEs, and they are 
more frequent in patients who have developed anti-chimeric 
antibodies, those using infliximab in an as-needed fashion, 
and those not being treated concurrently with methotrexate 
or cyclosporine.66,73 Infusion reactions present typically as 
fever, chills, headache, flushing, nausea, dyspnea, dysgeusia, 
pruritus, and urticaria; they present less frequently as chest 
pain, hypertension, hypotension, or anaphylaxis. These 
reactions can usually be managed by slowing the infusion 
rate or stopping treatment.66 Other common AEs include 
infection, increased LFTs, pruritus, and serum sickness. 
There exist rare reports of anaphylaxis, exacerbation of or 
new-onset CHF, cytopenia, hepatitis, interstitial pneumonitis 
or fibrosis, leukocytoclastic vasculitis, lupus erythematosus 
syndrome, malignancy (eg, Hodgkin’s lymphoma, CTCL, 
NMSC, hepatosplenic T-cell lymphoma), MS or other 
demyelinating disease, optic neuritis, pancreatitis, seizure, 
sepsis, and severe infections.66,68,72,73,75
Contraindications for infliximab use include chronic, 
active, serious, and recurrent infection, active TB, latent 
TB in the absence of chemoprophylaxis, hepatitis B, MS 
and other demyelinating disease, a first-degree relative with 
MS, NYHA class III or IV CHF, pregnancy or lactation, 
and hypersensitivity to infliximab, murine proteins, or 
other ingredients. During treatment with infliximab, 
patients should avoid live and live-attenuated vaccines. 
Table 3 lists monitoring recommendations for all TNF-α 
inhibitors.
Adalimumab
Adalimumab is a fully human TNF-α monoclonal IgG1 
antibody which blocks soluble and membrane-bound 
TNF-α from binding their natural receptors.80 It is currently 
Table 3 recommended monitoring during treatment with tumor 
necrosis factor-alpha inhibitors
In all patients:
  Periodic history and physical examination
  Periodic liver function tests
  Periodic complete blood count
  Yearly tuberculosis skin test (PPD)
In patients with hepatitis C:
  Periodic monitoring of liver function tests
  Periodic hepatitis C viral load
Abbreviation: PPD, purified protein derivative.Clinical, Cosmetic and Investigational Dermatology 2009:2 120
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flushing, interstitial pneumonitis or fibrosis, leukocytoclastic 
vasculitis, lupus erythematosus syndrome, malignancy 
(eg, Hodgkin’s lymphoma, CTCL, NMSC), menorrhagia, 
MS and other demyelinating disease, sepsis, and severe 
infection.50,66,68,69,80–82
Contraindications for adalimumab use include chronic, 
active, serious, and recurrent infection, active TB, latent 
TB in the absence of chemoprophylaxis, hepatitis B, MS 
and other demyelinating disease, first-degree relative with 
MS, NYHA class III or IV CHF, pregnancy or lactation, and 
hypersensitivity to adalimumab or its ingredients. During 
treatment with adalimumab, patients should avoid live and 
live-attenuated vaccines. Table 3 lists monitoring recom-
mendations for all TNF-α inhibitors.
Alefacept
In January 2003, alefacept became the first biologic agent 
approved by the FDA for the treatment of moderate to severe 
plaque psoriasis in adults who are candidates for systemic or 
ultraviolet therapy. Alefacept is a fully human fusion protein 
which acts to prevent the interaction between lymphocyte 
function-associated antigen-3 (LFA-3) and CD2. This blocks 
the activation of T cells, thus modifying the inflammatory 
process. Additionally, alefacept’s immunoglobulin G1 
domain interacts with natural killer cells to induce apoptosis 
of T cells. Both actions preferentially target memory/effector 
T cells, which have a high level of CD2 expression.84
The marketed dosing regimen of alefacept for psoriasis 
is a 12-week course of 15 mg intramuscularly (IM) given 
once weekly.97 An additional 12-week course may be 
given after 12 or more weeks off of treatment if the CD4+ 
lymphocyte count is within the normal range. Phase I studies 
showed alefacept to be well-tolerated when administered via 
30-second IV bolus or 30-minute IV infusion as well as IM;85,86 
however, pharmacokinetic studies favor IV bolus and IM 
administration. Phase III data (Table 2) confirm the efficacy 
of IV and IM alefacept for plaque-type psoriasis.87–90 In an 
attempt to achieve more rapid or complete response than the 
approved regimen (15 mg IM QW), Cafardi et al91 performed 
a small-scale comparison study of high-dose alefacept (30 mg 
IM QW for 12 weeks) versus loading dose followed by main-
tenance therapy (30 mg IM QW for 6 weeks + 15 mg IM QW 
for 6 weeks). There was no difference in efficacy between the 
groups, but there was a higher rate of adverse events in the 
group receiving higher doses of alefacept. Thus the dosing 
regimen remains 15 mg IM QW for a 12-week course.
Efficacy data from clinical trials of alefacept via both IV 
and IM routes as treatment for chronic plaque psoriasis 
FDA-approved for treating moderate to severe psoriasis, 
moderate to severe PsA, adult rheumatoid arthritis, juvenile 
rheumatoid arthritis in patients as young as 4 years old, anky-
losing spondylitis, and Crohn’s disease.27,46,50,66 For psoriasis, 
adalimumab is administered SC at a dose of 80 mg the first 
week, followed by 40 mg the next week and every other week 
(EOW) thereafter. For PsA, adalimumab is administered SC 
at 40 mg EOW.
Clinical response to adalimumab is substantial and 
rapid, with statistically significant improvement in PASI 
occurring as early as 1 week after initiation of treatment.80,81 
One meta-analysis reported that adalimumab has superior 
efficacy in treating moderate to severe psoriasis when 
compared to etanercept, efalizumab, alefacept, methotrexate, 
cyclosporine, acitretin, and fumaric acid esters.74 Rebound is 
uncommon upon discontinuation of adalimumab, but clinical 
response is better maintained with continuous than as-needed 
therapy.82 Sustained clinical response has been noted for as 
long as 60 weeks with continuous adalimumab treatment.80 
A relatively small proportion of patients experience loss of 
adalimumab efficacy with continued use.80,82 In one phase 
III active comparator trial, adalimumab demonstrated 
significantly higher efficacy and was better tolerated than 
methotrexate.81
Similar to etanercept, the slow absorption rate following 
SC administration, slow elimination rate, and appropriate 
dosing frequency give adalimumab a smooth and uniform 
concentration-time profile, minimizing the occurrences 
of overexposure and resultant adverse events, as well as 
underexposure and consequent symptom recurrence.52,53
Like etanercept, adalimumab is administered via a 
fixed-dose regimen and does not take the patient’s weight 
into account. In a recent study of 144 patients with psoriasis 
and PsA treated with adalimumab, PASI 50 response was 
achieved by significantly more patients with BMI less than 
30 (79%) than obese patients with BMI 30 or higher (58%).83 
This supports the notion that adalimumab may be less 
efficacious in treating heavier patients than normal-weight 
individuals.
Several clinical trials have reported the efficacy and safety 
of adalimumab in treating psoriasis and PsA (Table 2). There 
are, however, less data available for adalimumab than for 
etanercept and infliximab, since adalimumab is the newest 
of the three TNF-α inhibitors.
The most common AEs associated with adalimumab use 
are infection, injection site reaction, increased LFTs, and 
pruritus. There exist rare reports of anaphylaxis, angioedema, 
exacerbation of or new-onset CHF, cytopenia, fever, Clinical, Cosmetic and Investigational Dermatology 2009:2 121
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are summarized in Table 2. In general, up to one-third of 
patients achieve PASI 75 response during or after treatment 
with alefacept. Patients who achieve a physician’s global 
assessment (PGA) score of “clear” or “almost clear” do 
not, in general, require further anti-psoriasis treatment for 
10 months following a course of alefacept.85
Alefacept has been studied in but is not FDA-approved 
for PsA. In a phase II study, 185 patients received 12 weeks 
of methotrexate (MTX) plus either alefacept or placebo 
followed by 12 weeks of treatment with methotrexate 
alone.92 At week 24, 54% of patients in the alefacept + MTX 
group and 23% in the placebo + MTX group achieved at least 
a 20% decrease in the American College of Rheumatology 
response criteria (ACR-20). Further studies are needed 
to confirm the efficacy of alefacept in the treatment of 
psoriatic arthritis.
Per data from phase II and III randomized controlled 
trials, patients receiving alefacept have significantly greater 
improvements in dermatology-related quality of life (QOL) 
measures than patients receiving placebo.93,94 This improve-
ment is sustained up to twelve weeks after completion of 
the treatment course, and a second 12-week course provides 
additional QOL benefit.95 PASI 50 or greater response is asso-
ciated with significantly greater improvement in QOL scores, 
and alefacept therapy does not negatively impact QOL.
AEs reported in patients treated with alefacept are 
generally mild. Adverse events reported with at least 5% 
higher incidence with alefacept than placebo are chills, 
headache, pruritus, infection, rhinitis, injection site pain, 
injection site inflammation, and accidental injury (Table 2). 
The majority of infectious AEs reported with alefacept are 
due to the common cold.
Consistent with its mechanism of action, alefacept is 
known to cause a dose-dependent reduction in the total 
number of circulating lymphocytes as well as CD4+ and 
CD8+ memory T lymphocyte subsets.85 The reduction in 
CD4+ T lymphocyte (CD4) count correlates with disease 
activity.96 The vast majority of patients experience a return 
in CD4 count to within normal limits by 12 weeks following 
cessation of therapy.96 Current recommendations are to 
monitor CD4 count weekly throughout the treatment course, 
to withhold one dose for CD4 count less than 250 cells per 
microliter, and to discontinue therapy if CD4 count remains 
under 250 cells per microliter for 1 month.97 There have been 
no reports of opportunistic infection related or unrelated 
to CD4 count, increased risk of TB or viral reactivation, 
or increased incidence of malignancy, even with repeated 
courses of alefacept.98
The addition of localized use of topical corticosteroids 
provides no increased efficacy over alefacept alone and in 
fact is associated with further decrease in circulating memory 
T-cells over alefacept with vehicle.99 In another report, 
systemic anti-psoriasis therapy was added to alefacept in a 
small group of patients.100 Concomitant therapies used were 
methotrexate (n = 4), acitretin (n = 2), and cyclosporine 
(n = 1). Combination alefacept + systemic anti-psoriasis 
therapy led to slight increase in efficacy with no impact on 
CD4 count. Krueger et al89 report on an open-label study of 
449 patients with plaque psoriasis treated with up to three 
12-week courses of alefacept. Approximately one-third of 
patients were treated with alefacept alone or in combination 
with low-potency topical therapy, one-third were treated 
with alefacept plus medium- to high-potency topical 
therapy, and one-third were treated with alefacept plus a 
systemic or ultraviolet B (UVB) therapy. Because patients 
were permitted to receive different concomitant therapies 
between courses, the study was not powered to compare 
efficacy between therapies. Combination therapy did improve 
efficacy, however, particularly alefacept plus UVB. The 
improved efficacy of treatment with alefacept plus UVB 
over alefacept alone has been demonstrated in two other 
open-label clinical trials.90,101
Efalizumab
Efalizumab is a monoclonal humanized form of a murine 
antibody directed against CD11a, the α subunit of lympho-
cyte function-associated antigen-1 (LFA-1). By binding to 
CD11a, efalizumab inhibits cutaneous T cell trafficking,102 
T cell activation, and T cell adhesion to keratinocytes.103 
In 2003 it was approved by the FDA for continuous treatment 
of moderate to severe plaque psoriasis for adults who are 
eligible for systemic therapy, and in 2004 it was approved by 
the European Medicines Agency for adults who have failed 
to respond to or are intolerant of other systemic therapies. 
The marketed regimen of efalizumab use was one initial dose 
of 0.7 mg/kg SC followed by weekly injections of 1 mg/kg 
SC to a maximum 200 mg. In April 2009, efalizumab 
was withdrawn from the market based on several reports 
of progressive multifocal leukoencephalopathy (PML) in 
patients being treated with efalizumab.
A phase III dose-finding trial demonstrated significantly 
superior efficacy of each of 3 doses of efalizumab (1, 2, and 
4 mg/kg/week) to placebo and provided evidence supporting 
weekly dosing over EOW dosing.104 This and other studies 
showed that increasing the weekly SC dose from 1 mg/kg 
to 2 mg/kg did not achieve a higher rate of response.105 Clinical, Cosmetic and Investigational Dermatology 2009:2 122
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Data from several phase III studies support continuous use 
of efalizumab dosed at 1 mg/kg SC QW in patients with good 
initial clinical response.105–108 Efalizumab also demonstrated 
efficacy in treating palmoplantar psoriasis in several case 
reports and small open-label pilot studies.109–115 Treatment 
with efalizumab is also associated with significant improve-
ment in dermatology-related quality of life and psoriasis 
symptoms severity measures.116 Efalizumab has been shown 
to be ineffective in the treatment of psoriatic arthritis.117
The incidence of AEs reported in clinical trials of 
efalizumab are reported in Table 2. The most frequent 
AEs are flu-like symptoms: headache, chills, nausea, and 
myalgias are reported more frequently in patients receiving 
efalizumab than those receiving placebo. These are typically 
mild and acute, and their incidence decreases with ongoing 
treatment.118 In large RCTs, the frequency of SAEs was not 
significantly different in patients treated with efalizumab 
compared with placebo (Table 2). There have been reports of 
both immune-mediated thrombocytopenia119 and autoimmune 
hemolytic anemia120 within the first 6 months of treatment 
with efalizumab for psoriasis. These events are rare but 
serious, and guidelines suggest monitoring complete blood 
counts in patients on efalizumab.66
Both worsening of psoriasis and new-onset arthritis 
have been reported during therapy with efalizumab. Pooled 
data from four placebo-controlled trials indicate that the 
incidence of psoriasis adverse events, including worsening 
disease and onset of new psoriasis morphologies was 3% 
in patients treated with efalizumab and 1% in those treated 
with placebo. In a small retrospective analysis, ten patients 
with psoriasis-related AEs during long-term efalizumab 
treatment were treated with intercurrent cyclosporine.121 
This combination therapy was generally well-tolerated and 
effectively controlled the relapse. No patient experienced a 
serious adverse event or psoriasis rebound or flare.
The FDA has received reports of three confirmed cases 
and one possible unconfirmed case of progressive multifocal 
leukoencephalopathy (PML), a life-threatening central 
nervous system infection in patients being treated with 
efalizumab for psoriasis.122 This initially led to a black box 
warning for PML and efalizumab, followed in April 2009 by 
efalizumab being withdrawn from the consumer market. All 
patients treated with efalizumab are expected to discontinue 
therapy by July 2009.
Psoriasis rebound or flare following abrupt withdrawal 
of efalizumab is well documented and must be considered 
when discontinuing efalizumab. This flare may be seen 
as soon as after missing a single dose of efalizumab.123 
The post-efalizumab discontinuation flare may manifest as 
generalized erythrodermic or pustular psoriasis,124 guttate 
psoriasis,125 or recurrent plaque psoriasis. One study revealed 
efalizumab-responsive patients to be less likely to experience 
rebound than non-responders.126 Management of the post-
efalizumab flare should be approached on a case-by-case 
basis. One must consider comorbidities, prior and planned 
future treatment, and contraindications to other psoriasis 
therapies. Cyclosporine and methotrexate have been proven 
efficacious in many but not all127 reports. In an open-label 
study comparing post-efalizumab treatments, cyclosporine 
and methotrexate were superior to systemic corticosteroids, 
retinoids, or combined corticosteroids and methotrexate 
in preventing rebound.128 In one study of 130 patients, no 
patient who was placed on cyclosporine or methotrexate 
immediately on discontinuation of efalizumab experienced 
rebound.126 These findings suggest that when transitioning a 
patient from efalizumab to another biologic agent, one may 
consider bridging therapy with cyclosporine or methotrexate 
in an attempt to decrease the likelihood and/or severity of 
psoriasis rebound until the new agent has taken effect.
Ustekinumab
In recent years, biologic agents targeting IL-12/23 have 
shown great promise.129 Both agents target the p40 subunit 
shared by IL-12 and IL-23, which are over-expressed in 
psoriasis plaques.130 The so-called “anti-IL-12” drugs include 
ustekinumab (CNTO 1275) and ABT-874. Ustekinumab 
is currently in the final approval stages at the FDA, while 
ABT-874 is currently in early phase III studies.
Ustekinumab (formerly CNTO-1275) is a human 
monoclonal antibody that binds with high affinity and 
specificity to p40, thereby preventing interaction with 
cell-surface IL12Rβ1 receptors. It has been proven 
efficacious in the treatment of Crohn’s disease131 in addition 
to psoriasis and psoriatic arthritis. It has been unsuccessful 
in the treatment of MS.132 A phase I first-in-human study 
demonstrated concentration-dependent improvement of 
psoriasis lesions following a single IV dose of ustekinumab.133 
Twelve of 18 subjects (67%) achieved at least PASI 
75 improvement between 8 and 16 weeks following 
administration. Dose-finding studies have determined that 
ustekinumab is efficacious in the treatment of psoriasis at 
45 to 90 mg SC every 8 to 12 weeks. The marketed dosing 
regimen is expected to be 45 mg SC every 12 weeks.
Efficacy data from clinical trials of ustekinumab 
for moderate to severe chronic plaque psoriasis134 are 
summarized in Table 2. In the first comparator trial of two Clinical, Cosmetic and Investigational Dermatology 2009:2 123
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biologic agents, ustekinumab showed superiority compared 
with etanercept in the treatment of moderate to severe plaque 
psoriasis.135 In the study, ustekinumab 45 mg or 90 mg SC 
at weeks 0 and 4 was compared with etanercept 50 mg SC 
twice weekly from weeks 0 to 12. In the ustekinumab groups, 
68% and 74% of participants (45 mg and 90 mg, respectively) 
achieved PASI 75 at week 12, compared with 57% of patients 
on etanercept.
In large phase III randomized controlled trials, participants 
treated with ustekinumab experienced greater decreases in 
dermatology life quality index (DLQI) scores than did placebo-
treated participants. At week 12 in a trial of 1230 patients, 
significantly more subjects treated with ustekinumab 45 mg 
(55%) and 90 mg (56%) reached DLQI score of 0 or 1 than 
did those receiving placebo (3%).136 Results were similar in 
another phase III study of 766 patients: DLQI of 0 or 1 was 
achieved by 53% of those treated with ustekinumab 45 mg, 
52% treated with ustekinumab 90 mg, and 6% receiving 
placebo.137 The efficacy results of these two large phase III 
trials demonstrated that 67% of patients in both studies treated 
with 45 mg of ustekinumab reached PASI 75 at week 12 
and that 66% and 76% of patients treated with 90 mg of 
ustekinumab reached PASI 75 at 12 weeks.
In a phase II double-blind, randomized, placebo-
controlled crossover study of 146 adults, ustekinumab 
significantly reduced signs and symptoms of active psoriatic 
arthritis compared with placebo.138 Active psoriatic arthritis 
was defined as 3 or more swollen joints and 3 or more tender 
joints plus either C-reactive protein (CRP) of at least 15 mg/L 
or morning stiffness for at least 45 minutes. Patients were 
required to have been diagnosed with PsA at least 6 months 
prior to enrollment in the study. At week 12, 42% of patients 
treated with ustekinumab (either 90 mg or 63 mg SC weekly 
at weeks 0–3) and 14% of patients receiving placebo achieved 
ACR-20 response. Patients were also required to have active 
plaque psoriasis with a target lesion of at least 2 cm diameter, 
and ustekinumab also improved cutaneous lesions compared 
to placebo. Of the 124 (85%) of patients with at least 3% or 
greater body surface area (BSA) involvement with psoriasis, 
52% of ustekinumab-treated patients (33 of 63) and 5% of 
placebo-treated patients (3 of 55) achieved PASI 75 response 
at week 12.
The incidence of adverse events in clinical trials of 
ustekinumab is summarized in Table 2. The most common 
AEs are upper respiratory tract infection, headache, 
nasopharyngitis, injection site erythema, and arthralgias. 
In trials conducted to date, there does not appear to be a 
significant difference in the incidence of serious adverse 
events, infectious adverse events, malignancy, cardiovascular 
events, or adverse events leading to treatment discontinua-
tion. There has also been no dose-response in adverse event 
incidence or severity.
ABT -874
ABT-874 is a fully human antibody with high affinity for 
the shared p40 subunit of IL-12 and IL-23. This antibody 
displays very potent in vitro neutralization of IL-12, was very 
effective in animal models, and has demonstrated clinical 
efficacy in the treatment of psoriasis in human studies. 
ABT-874 is also being investigated for use in the treatment 
of Crohn’s disease.
Phase II data reveal substantial and statistically 
significantly superior efficacy of ABT-874 at each of five 
different dosing regimens compared with placebo.139 This 
includes a single dose of ABT-874, after which 63% of 
patients demonstrated PASI 75 response 3 months later. 
These data are seen in Table 2. This effect is often sustained 
weeks to months following cessation of therapy.
Safety data thus far indicate that subjects treated with 
ABT-874 are not statistically significantly more likely than 
those treated with placebo to experience serious infectious, or 
malignant adverse events. Further safety and efficacy data are 
currently being obtained via numerous phase III studies.
Summary
When selecting a biologic agent for use in a patient with pso-
riasis, one must consider a number of characteristics both of 
the patient and of the medication. Patient-specific factors to 
consider include psoriasis morphology and severity, state 
of health, comorbidities, body mass index, concomitant 
therapy, and adherence. Medication-specific consider-
ations include efficacy, adverse events and contraindica-
tions, method of administration, and physician experience 
with the agent. Unfortunately there is no simple way 
to determine which patient to treat with which agent. 
The choice of which agent to utilize is best made after 
obtaining a careful history and physical examination 
along with a detailed discussion with the patient about 
the advantages and disadvantages of all of the five cur-
rently available biologic therapies. Prior to initiating 
therapy with any biologic agent, appropriate screen-
ing studies include TB testing, complete blood count 
(CBC), hepatic function panel, hepatitis profile, and 
pregnancy testing as appropriate. Acceptable methods 
of TB screening include the purified protein derivative 
skin test and QuantiFERON Gold test (where available). Clinical, Cosmetic and Investigational Dermatology 2009:2 124
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Chest x-ray may also be utilized based on results of 
screening tests and in special circumstances as indicated 
by Centers of Disease Control and Prevention (CDC) 
guidelines.66,140 Re-testing for TB should be performed in 
all patients who are exposed to or demonstrate symptoms 
of TB, and annually in all patients being treated with 
biologic agents. Alefacept, adalimumab, etanercept, and 
infliximab are pregnancy category B medications, and 
efalizumab is a pregnancy category C medication.
Patients initiating treatment with alefacept must have 
a CD4 count done prior to initiating treatment and then 
biweekly during treatment. Alefacept dose should be held 
for CD4 count less than 250 cells per microliter. Alefacept 
is contraindicated in HIV-infected patients, and because new 
CDC guidelines recommend HIV testing in all patients who 
present for medical care,141 one may consider HIV testing in 
all patients being screened for any biologic agent.
Anti-TNF-α agents are contraindicated in the presence of 
serious infections such as TB, opportunistic infections, and 
hepatitis B. They should also not be used with live vaccines. 
Biologically inactive or recombinant vaccine use is accept-
able in patients being treated with TNF-α antagonists, but 
the immune response of the vaccine may be compromised. 
Because of the association between TNF-α inhibitors and 
demyelinating disease, they should not be used in patients 
with these diseases. First-degree relatives of patients with 
MS have an increased risk of developing MS themselves; 
one should therefore avoid treatment with TNF-α inhibitors 
in first-degree relatives of patients with MS. Use of TNF-α 
inhibitors may lead to new-onset or exacerbation of CHF. 
Caution should therefore be exercised in patients with CHF, 
particularly those with left ventricular ejection fraction less 
than 50%. Use of TNF-α antagonists should be avoided in 
patients with NYHA Functional Class 3 or 4 CHF, and inf-
liximab use at doses greater than 5 mg/kg is contraindicated 
in these patients. Etanercept is contraindicated in sepsis. 
Patients who are treated with TNF-α inhibitors should be 
alerted of common adverse events (such as the painful 
injection site reaction seen in some patients treated with 
adalimumab) as well as rare but serious adverse events such 
as drug-induced lupus, serum sickness, and malignancy 
(including hepatosplenic T-cell lymphoma in children treated 
with infliximab).
The biologic agents have greatly increased the treatment 
choices for patients with moderate to severe psoriasis as well 
as those with moderate to severe PsA. These newer agents 
not only offer new choices, but based upon the short- and 
intermediate-term data that are currently available, the 
biologic agents also appear to offer safer, more effective, 
and convenient therapies.
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